NCT00728208已完成1 期
A Placebo-controlled, Single-blind, Randomised, Parallel Group, 28-day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 in Healthy Young and Elderly, Male and Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Main pharmacokinetic parameters after single and repeat administration: Cmax, tmax, AUC(0-t), AUC(0-tau), Ctau and Ro.
研究概览
简要总结
This study will consist of 4 parallel cohorts of healthy volunteers (elderly male, elderly female, young male and young female). Subjects will receive either GSK372475 1.5mg or placebo for 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by a responsible physician, based on a medical evaluation including medical and psychiatric history (including family history), full physical examination, laboratory tests and cardiac monitoring.
- •Male or female between 18 and 45 years of age (young healthy population) and >65 years old (elderly population).
- •A female subject is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- •Child-bearing potential and agrees to use of specific contraception methods. Use of oral contraception is permitted.
- •BMI within the range 19 - 29 kg/m2 (inclusive).
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
- •Able to swallow and retain oral medication
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular or other heart disease, glaucoma, diabetes, hepatic, neurologic (e.g. including but not limited to seizures, stroke, cerebrovascular disease or other brain conditions), or allergic disease (except for untreated, asymptomatic, seasonal allergies at time of dosing).
- •Psychiatric illness currently or within the past year, or any lifetime history of bipolar disorder, major depressive disorder, anxiety disorder, schizophrenia or other psychotic disorder, or substance abuse or dependence (except past history of nicotine abuse/dependence).
- •Subjects who, in the investigator's judgment, pose a suicidal or homicidal risk, or any subject with a history of suicidal or homicidal attempts or behaviour.
- •The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening (with the exception of phase I hepatic impairment studies, oncology studies, hepatitis, hepatic fibrosis, or HIV studies).
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as:
- •an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 60 days i.e. 5 half-lives.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- •Lactating females.
- •Administration of a monoamine oxidase inhibitor (MAOI) within 30 days prior to Study Day 1, or anticipated use within 12 weeks following the last dose of study drug.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •Consumption of grapefruit juice or grapefruit or cruciferous vegetables (e.g. broccoli, Brussels sprouts, cabbage, cauliflower, chard, kale, mustard greens, rutabagas and turnips) and charbroiled foods within 7 days prior to first dose of study medication until follow-up.
- •Controlled or uncontrolled hypertension, or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at screening or prior to the first dose of study medication.
研究组 & 干预措施
GSK372475
Experimental
Drug
干预措施: GSK372475 (Drug)
结局指标
主要结局
Main pharmacokinetic parameters after single and repeat administration: Cmax, tmax, AUC(0-t), AUC(0-tau), Ctau and Ro.
时间窗: pre-dose to 24 hours post dose
次要结局
- Safety and tolerability endpoints, including adverse events (AEs), vital signs, electrocardiograms (ECGs) and clinical laboratory tests.(from dosing to follow-up)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS)Gut MicrobiotaImmune FunctionNCT01586247University of Reading40
已完成
不适用
A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy VolunteersGut MicrobiotaBowel FunctionImmune FunctionPlasma LipidsNCT01545219University of Reading44
已完成
1 期
A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeOsteoarthritis of the KneeNCT00944892Regeneron Pharmaceuticals200
已完成
4 期
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCystic FibrosisNCT02875366Vertex Pharmaceuticals Incorporated70
撤回
2 期
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DMNASH - Nonalcoholic SteatohepatitisNAFLDT2DM (Type 2 Diabetes Mellitus)NCT03291249Tiziana Life Sciences LTD